Concepedia

Andrés Salmerón

AS

10

Publications

955

Citations

10

H-Index

1996

Active since

Affiliations

Constellation Pharmaceuticals (United States)(Current)

Abbott (United States)

Andrés Salmerón is an author at Constellation Pharmaceuticals (United States) specializing in medicine, signal transduction, and cell signaling.

ORCID

Top concepts

Publications per year

1996–2023

10

Publications

10

Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase.

Andrés Salmerón, Tahir Ahmad, Graeme W. Carlile et al. · The EMBO Journal · 1996 · 301 citations

, , +7

BET bromodomain inhibition suppresses TH17-mediated pathology

Deanna A. Mele, Andrés Salmerón, Srimoyee Ghosh et al. · The Journal of Experimental Medicine · 2013 · 236 citations · Full text

, , +15

βTrCP-Mediated Proteolysis of NF-κB1 p105 Requires Phosphorylation of p105 Serines 927 and 932

Valérie Lang, Julia Janzen, Gregory Zvi Fischer et al. · Molecular and Cellular Biology · 2002 · 130 citations · Full text

Direct Phosphorylation of NF-κB1 p105 by the IκB Kinase Complex on Serine 927 Is Essential for Signal-induced p105 Proteolysis

Andrés Salmerón, Julia Janzen, Yasmina Soneji et al. · Journal of Biological Chemistry · 2001 · 129 citations · Full text

Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition

Srimoyee Ghosh, Alexander M. Taylor, Melissa Chin et al. · Journal of Biological Chemistry · 2016 · 76 citations · Full text

, , +9

Rows per page

1–5 of 10